Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,211.66
(
0.02%
)
News Focus
News Focus
Post# of 257483
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: maverick_1 post# 194464

Wednesday, 08/19/2015 1:02:04 AM

Wednesday, August 19, 2015 1:02:04 AM

Post# of 257483
>>Gregory A. Demopulos, M.D Phd Stanford grad

Well Dr. Demopulos would have served his shareholders better over the last four years if he hadn't been continually promising a partnership "real soon now" on some of the GPCR projects.

This MASP-2 project has always been the most interesting by far of the projects that the company has discussed. It's not just a drug - they own a lot of the IP surrounding the pathway.


Peter

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today